OBJECTIVES: We investigated whether changes in quality of life (QoL) during treatment could predict survival in stage IV pancreatic cancer. METHODS: Quality of life was evaluated at baseline and after 3 months of treatment using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) in 186 patients with stage IV pancreatic cancer. Cox regression evaluated the prognostic significance of baseline and changes in QoL scores after adjusting for age, sex, and treatment history. RESULTS: One hundred twenty-one patients were males and 65 were females. One hundred twenty-seven patients' condition was newly diagnosed, whereas 59 were previously treated. The mean age at diagnosis was 55.1 years. Baseline QoL scale predictive of survival upon multivariate analysis was global health (hazard ratio, 0.88; 95% confidence interval, 0.81-0.95; P = 0.001). On multivariate analysis, QoL change variable that was significantly predictive of survival after 3 months of treatment was cognitive function (hazard ratio, 0.89; 95% confidence interval, 0.79-0.99; P = 0.04). CONCLUSIONS: This study provides preliminary evidence to indicate that patients with stage IV pancreatic cancer who have a better global health at baseline as well as those whose cognitive function improves within 3 months of treatment have a significantly increased probability of survival.
OBJECTIVES: We investigated whether changes in quality of life (QoL) during treatment could predict survival in stage IV pancreatic cancer. METHODS: Quality of life was evaluated at baseline and after 3 months of treatment using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) in 186 patients with stage IV pancreatic cancer. Cox regression evaluated the prognostic significance of baseline and changes in QoL scores after adjusting for age, sex, and treatment history. RESULTS: One hundred twenty-one patients were males and 65 were females. One hundred twenty-seven patients' condition was newly diagnosed, whereas 59 were previously treated. The mean age at diagnosis was 55.1 years. Baseline QoL scale predictive of survival upon multivariate analysis was global health (hazard ratio, 0.88; 95% confidence interval, 0.81-0.95; P = 0.001). On multivariate analysis, QoL change variable that was significantly predictive of survival after 3 months of treatment was cognitive function (hazard ratio, 0.89; 95% confidence interval, 0.79-0.99; P = 0.04). CONCLUSIONS: This study provides preliminary evidence to indicate that patients with stage IV pancreatic cancer who have a better global health at baseline as well as those whose cognitive function improves within 3 months of treatment have a significantly increased probability of survival.
Authors: Suvina Amin; Seongjung Joo; Sandra Nolte; Hyun Kyoo Yoo; Nikunj Patel; Hilary F Byrnes; Sara Costa-Cabral; Colin D Johnson Journal: BMC Cancer Date: 2022-05-20 Impact factor: 4.638
Authors: Momar Diouf; Thomas Filleron; Anne-Laure Pointet; Anne-Claire Dupont-Gossard; David Malka; Pascal Artru; Mélanie Gauthier; Thierry Lecomte; Thomas Aparicio; Anne Thirot-Bidault; Céline Lobry; Francine Fein; Olivier Dubreuil; Bruno Landi; Aziz Zaanan; Julien Taieb; Franck Bonnetain Journal: Qual Life Res Date: 2015-11-28 Impact factor: 4.147
Authors: Joseph M Herman; Helen Kitchen; Arnold Degboe; Natalie V J Aldhouse; Andrew Trigg; Mary Hodgin; Amol Narang; Colin D Johnson Journal: Qual Life Res Date: 2019-07-04 Impact factor: 4.147
Authors: Miss Charlotte L Moss; Ajay Aggarwal; Asad Qureshi; Benjamin Taylor; Teresa Guerrero-Urbano; Mieke Van Hemelrijck Journal: Health Qual Life Outcomes Date: 2021-01-15 Impact factor: 3.186